Recent News

• 12.03.2025 - bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
• 11.14.2025 - bioAffinity Technologies Reports Third Quarter 2025 Financial Results
• 11.05.2025 - bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
• 10.28.2025 - bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
• 10.20.2025 - bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
• 10.16.2025 - bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

Recent Filings

• 11.14.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - 8-K Current report
• 11.12.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 11.07.2025 - DEF 14A Other definitive proxy statements
• 11.05.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 8-K Current report
• 10.28.2025 - 8-K Current report
• 10.28.2025 - EX-99.1 EX-99.1
• 10.27.2025 - PRER14A Preliminary Proxy Soliciting materials